A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia ® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
Condition:   Postmenopausal Women With Osteoporosis Interventions:   Drug: MB09 (denosumab biosimilar);   Drug: EU-Prolia;   Dietary Supplement: Elemental Calcium;   Dietary Supplement: Vitamin D Sponsor:   mAbxience S.A Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

Ionized Magnesium Balance During Hemodialysis Session
Condition:   Chronic Kidney Diseases Interventions:   Biological: Lymphatic drainage;   Biological: Total and ionized magnesium;   Biological: Total and ionized calcium Sponsor:   University Hospital, Montpellier Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia ® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
Condition:   Postmenopausal Women With Osteoporosis Interventions:   Drug: MB09 (denosumab biosimilar);   Drug: EU-Prolia;   Dietary Supplement: Elemental Calcium;   Dietary Supplement: Vitamin D Sponsor:   mAbxience S.A Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

Ionized Magnesium Balance During Hemodialysis Session
Condition:   Chronic Kidney Diseases Interventions:   Biological: Lymphatic drainage;   Biological: Total and ionized magnesium;   Biological: Total and ionized calcium Sponsor:   University Hospital, Montpellier Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia ® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
Condition:   Postmenopausal Women With Osteoporosis Interventions:   Drug: MB09 (denosumab biosimilar);   Drug: EU-Prolia;   Dietary Supplement: Elemental Calcium;   Dietary Supplement: Vitamin D Sponsor:   mAbxience S.A Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

Ionized Magnesium Balance During Hemodialysis Session
Condition:   Chronic Kidney Diseases Interventions:   Biological: Lymphatic drainage;   Biological: Total and ionized magnesium;   Biological: Total and ionized calcium Sponsor:   University Hospital, Montpellier Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia ® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
Condition:   Postmenopausal Women With Osteoporosis Interventions:   Drug: MB09 (denosumab biosimilar);   Drug: EU-Prolia;   Dietary Supplement: Elemental Calcium;   Dietary Supplement: Vitamin D Sponsor:   mAbxience S.A Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

Ionized Magnesium Balance During Hemodialysis Session
Condition:   Chronic Kidney Diseases Interventions:   Biological: Lymphatic drainage;   Biological: Total and ionized magnesium;   Biological: Total and ionized calcium Sponsor:   University Hospital, Montpellier Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia ® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
Condition:   Postmenopausal Women With Osteoporosis Interventions:   Drug: MB09 (denosumab biosimilar);   Drug: EU-Prolia;   Dietary Supplement: Elemental Calcium;   Dietary Supplement: Vitamin D Sponsor:   mAbxience S.A Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

Ionized Magnesium Balance During Hemodialysis Session
Condition:   Chronic Kidney Diseases Interventions:   Biological: Lymphatic drainage;   Biological: Total and ionized magnesium;   Biological: Total and ionized calcium Sponsor:   University Hospital, Montpellier Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia ® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
Condition:   Postmenopausal Women With Osteoporosis Interventions:   Drug: MB09 (denosumab biosimilar);   Drug: EU-Prolia;   Dietary Supplement: Elemental Calcium;   Dietary Supplement: Vitamin D Sponsor:   mAbxience S.A Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

Ionized Magnesium Balance During Hemodialysis Session
Condition:   Chronic Kidney Diseases Interventions:   Biological: Lymphatic drainage;   Biological: Total and ionized magnesium;   Biological: Total and ionized calcium Sponsor:   University Hospital, Montpellier Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials

Study of effect of nimodipine and acetaminophen on postictal symptoms in depressed patients after electroconvulsive therapy (SYNAPSE)
DiscussionWith this clinical trial, we will systematically study postictal EEG, MRI and clinical phenomena after ECT-induced seizures and will test the effects of vasodilatory treatment intending to reduce postictal symptoms. If an effect is established, this will provide a novel treatment of postictal symptoms in ECT patients. Ultimately, these findings may be generalized to patients with epilepsy.Trial registrationInclusion in SYNAPSE started in December 2019. Prospective trial registration number isNCT04028596 on the international clinical trial register on July 22, 2019. (Source: Trials)
Source: Trials - April 18, 2022 Category: Research Source Type: clinical trials

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
Conditions:   Cognitively Normal Older Adults;   Hypertension;   Subjective Cognitive Decline;   Family History of Dementia Intervention:   Drug: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) Sponsors:   Rong Zhang;   National Institute on Aging (NIA);   Texas Health Resources;   Michigan State University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2022 Category: Research Source Type: clinical trials